MLTX
MoonLake Immunotherapeutics
Set alert
11.78 USD -0.79 -6.28%
11.71 Day range 12.63
9.55 52-week range 22.16
- YTD
- -10.62%
- 1 year
- +20.08%
- Open
- 12.44
- Prev close
- 12.57
- Mkt cap
- 1.00B
- Vol
- 1.13M
- Avg vol
- 1.69M
- EPS
- -3.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.71
- High
- 12.63
- Forward P/E
- -3.54
- Beta
- 1.08
- Short ratio
- 4.01
- Inst. own
- 87.73%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 12.60
- 200-d avg
- 16.49
- 1y target
- 28.54
Financial health
Altman Z-Score
2.44 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 2
- P/E 1
- P/B 2
Valuation
P/E -3.7×
FY 2020 5y median -6.8× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 2.8×
FY 2020 5y median 6.0× FY 2025
P/FCF -4.3×
FY 2020 5y median -10.4× FY 2025
EV/EBITDA -2.7×
FY 2020 5y median -6.9× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -23.1%
FY 2020 5y median -9.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -74.7%
FY 2020 5y median -26.6% FY 2025
ROIC -64.4%
FY 2020 5y median -64.4% FY 2025
ROA -53.6%
FY 2020 5y median -53.6% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -71.1%
FY 2020 FY 2025
EPS (diluted) -86.8%
FY 2020 FY 2025
Free Cash Flow -67.4%
FY 2020 FY 2025
Financial Health
Current Ratio 9.3×
FY 2020 5y median 10.0× FY 2025
Quick Ratio 9.3×
FY 2020 5y median 10.0× FY 2025
Debt / Equity 0.2×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 1.2×
FY 2020 5y median 1.2× FY 2025
Interest Coverage -33.8×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31